Isabelle Vanden Bempt

Author

KU Leuven ORCID

Also Known As

I Vanden Bempt, I. V. Bempt, I. Vanden Bempt, I. Vanden Bempt, Isabelle Vanden Bempt, Isabelle Vanden Bempt

116

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

KU Leuven University of Antwerp VIB-KU Leuven Center for Cancer Biology Universitair Ziekenhuis Leuven Leiden University Medical Center

About

Isabelle Vanden Bempt is an author at KU Leuven specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	761
2	Cell Biology	4	4	261
3	Engineering	2	2	52
4	Health Sciences	2	2	166
5	Gastroenterology	1	1	45

Isabelle Vanden Bempt

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing Isabelle Vanden Bempt, Peter Van Loo, M. Drijkoningen, Journal of Clinical Oncology	2008	151
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma Oskar Marín-Béjar, Aljosja Rogiers, Michael Dewaele, Cancer Cell Health SciencesSkin CancerTumor HeterogeneityGeneticsMelanoma	2021	145
The E2F-Regulated Gene <i>Chk1</i> Is Highly Expressed in Triple-Negative Estrogen Receptor−/Progesterone Receptor−/HER-2− Breast Carcinomas Lieve Verlinden, Isabelle Vanden Bempt, Guy Eelen, Cancer Research Breast OncologyCancer BiologyTumor BiologyTranscriptional RegulationCancer Cell Biology	2007	142
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive Ben Van Calster, Isabelle Vanden Bempt, M. Drijkoningen, Breast Cancer Research and Treatment Breast OncologyMedicinePathologyCombined Steroid ReceptorBreast Cancer	2008	91
Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies Liesbeth Lenaerts, Nathalie Brison, Charlotte Maggen, EClinicalMedicine	2021	80
T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response Peter Van Loo, Thomas Tousseyn, Vera Vanhentenrijk, Haematologica	2009	72
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’ Patrick Schöffski, Olivier Mir, Bernd Kasper, European Journal of Cancer European OrganisationGastrointestinal Oncology‘ Cabogist ’MedicinePharmacology	2020	65
Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis Vanya Van Belle, Ben Van Calster, Olivier Brouckaert, Journal of Clinical Oncology	2010	57
Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D Stefan Timmerman, Anne‐Sophie Van Rompuy, Toon Van Gorp, Gynecologic Oncology Tumoral PathologyCancer RiskMedicineAdditional Genetic AnalysesPromise Classification	2020	57
Real‐time reverse transcription‐PCR and fluorescence <i>in‐situ</i> hybridization are complementary to understand the mechanisms involved in HER‐2/<i>neu</i> overexpression in human breast carcinomas Isabelle Vanden Bempt, Vera Vanhentenrijk, M. Drijkoningen, Histopathology	2005	52

Page 1